Insurance Dropping GLP-1 Coverage in 2026? What Changed and What to Do

Last updated September 22, 2026

If your insurance stopped paying for Wegovy or Zepbound this year, you’re far from alone. New state data released September 17 shows how fast commercial coverage for GLP-1 weight-loss drugs has contracted in 2026 — and fall open enrollment is your chance to do something about it for 2027.

Here’s what changed, what’s actually coming back, what self-pay costs right now, and the exact questions to ask before you pick next year’s plan.

The pullback, in numbers

Massachusetts’ Health Policy Commission reported that 112,000 fewer commercially insured residents used GLP-1s for weight loss between 2025 and the first quarter of 2026 — a 52% drop, after years of roughly doubling annually (GBH News, Sept. 17, 2026). The share of members using them fell sharply at the state’s largest insurers between late 2025 and early 2026:

It isn’t just one state. GoodRx’s coverage tracker estimated in July that more than 114 million people had no commercial coverage for Zepbound — about 17 million more than in 2025 (GoodRx).

What a typical cut looks like

Health New England’s change is a clear example of the pattern (Health New England):

• Wegovy, Zepbound and Saxenda no longer covered for weight loss for individual and small-group members as of January 1, 2026.
• Larger employers (100+ subscribers) can buy a rider to keep coverage — at extra cost.
• GLP-1s approved for type 2 diabetes (Ozempic, Mounjaro, Trulicity) stay covered for that diagnosis.

That last point is common across plans: coverage often depends on why the drug is prescribed, not just which drug it is.

What’s coming back

Not every change is a cut. CVS Caremark — one of the largest pharmacy benefit managers — announced on May 28 that Zepbound returns as a preferred drug on its standard commercial formularies October 1, 2026, and that it lifted its new-drug block on Foundayo (Lilly’s daily GLP-1 pill) as of June 1 where plans choose to cover it (CVS Health). Employers that customize their formulary can still opt out, so check your own plan.

On Medicare? A separate federal program now caps Wegovy, Zepbound and Foundayo at $50 a month for eligible enrollees through 2027 — see our Medicare GLP-1 Bridge guide.

If you’re paying out of pocket: current self-pay prices

Manufacturer self-pay programs have become the main alternative to insurance. Current list prices from the manufacturers:

Sources: NovoCare, Eli Lilly (Zepbound KwikPen), Eli Lilly (Foundayo). Prices change — confirm at checkout.

A word of caution: be skeptical of sellers promising “the same thing” for far less. The FDA sent warning letters to 30 telehealth companies over misleading compounded GLP-1 marketing in March 2026 (Venable LLP). For the full picture on legitimate routes, see how to get GLP-1s without insurance.

Open enrollment checklist: 6 questions to ask about any 2027 plan

1. Is my specific drug on the 2027 formulary — and for which diagnosis? “Covered for diabetes” is not “covered for weight loss.”
2. Does the plan exclude weight-loss drugs entirely? Look for “anti-obesity medications” or “weight loss drugs” in the exclusions list.
3. What are the prior authorization rules? BMI thresholds, required documentation, and how often it must be renewed.
4. Is there step therapy? Some plans require trying a cheaper drug first.
5. Which pharmacy benefit manager runs the plan? A CVS Caremark template formulary may cover Zepbound from October 1; a customized one may not.
6. What’s my real monthly cost after coverage? Compare the plan’s copay or coinsurance to the self-pay prices above — for some people, self-pay plus a cheaper premium wins.

If your employer offers an HSA or FSA, prescription medications are generally eligible expenses — confirm with your plan administrator.

Don’t lose momentum during a switch

Coverage gaps are when people run out, restart and fight side effects all over again. Track your remaining doses with our free GLP-1 Supply Tracker, and if a coverage change means switching medications, walk in prepared with our Doctor Visit Prep Kit.

Sources

• GBH News — Sharp decline in GLP-1 usage in 2026 as insurance companies drop coverage (Sept. 17, 2026)
• GoodRx — Tracking insurance coverage for GLP-1 weight-loss meds (reviewed July 10, 2026)
• Health New England — GLP-1 Coverage Update
• CVS Health — CVS Caremark expands GLP-1 coverage options (May 28, 2026)
• NovoCare — Wegovy self-pay pricing
• Eli Lilly — Zepbound KwikPen self-pay (March 16, 2026); Foundayo approval (April 1, 2026)

This article is for informational purposes only and is not medical, insurance or financial advice. Coverage and prices vary by plan and change often — confirm with your insurer, plan administrator and prescriber.